These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35644725)

  • 1. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study.
    Holmberg CJ; Ny L; Hieken TJ; Block MS; Carr MJ; Sondak VK; Örtenwall C; Katsarelias D; Dimitriou F; Menzies AM; Saw RP; Rogiers A; Straker RJ; Karakousis G; Applewaite R; Pallan L; Han D; Vetto JT; Gyorki DE; Tie EN; Vitale MG; Ascierto PA; Dummer R; Cohen J; Hui JY; Schachter J; Asher N; Helgadottir H; Chai H; Kroon H; Coventry B; Rothermel LD; Sun J; Carlino MS; Duncan Z; Broman K; Weber J; Lee AY; Berman RS; Teras J; Ollila DW; Long GV; Zager JS; van Akkooi A; Olofsson Bagge R
    Eur J Cancer; 2022 Jul; 169():210-222. PubMed ID: 35644725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of immune checkpoint inhibitors for in-transit melanoma.
    Nan Tie E; Lai-Kwon J; Rtshiladze MA; Na L; Bozzi J; Read T; Atkinson V; Au-Yeung G; Long GV; McArthur GA; Sandhu S; Saw R; Walpole E; Menzies A; Smithers M; Gyorki DE
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
    Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
    Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials.
    Olofsson Bagge R; Ny L; Ascierto PA; Hodi FS; Larkin J; Robert C; Schachter J; Weber JS; Long GV; van Akkooi ACJ
    Melanoma Res; 2021 Apr; 31(2):181-185. PubMed ID: 33625104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
    Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
    Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis.
    Heppt MV; Eigentler TK; Kähler KC; Herbst RA; Göppner D; Gambichler T; Ulrich J; Dippel E; Loquai C; Schell B; Schilling B; Schäd SG; Schultz ES; Matheis F; Tietze JK; Berking C
    Cancer Immunol Immunother; 2016 Aug; 65(8):951-9. PubMed ID: 27294607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
    Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
    Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prediction model for response to immune checkpoint inhibition in advanced melanoma.
    van Duin IAJ; Verheijden RJ; van Diest PJ; Blokx WAM; El-Sharouni MA; Verhoeff JJC; Leiner T; van den Eertwegh AJM; de Groot JWB; van Not OJ; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Stevense-den Boer MAM; Boers-Sonderen MJ; Kapiteijn E; Suijkerbuijk KPM; Elias SG
    Int J Cancer; 2024 May; 154(10):1760-1771. PubMed ID: 38296842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.
    van Not OJ; de Meza MM; van den Eertwegh AJM; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; van Breeschoten J; de Groot JB; Hospers GAP; Ismail RK; Kapiteijn E; Piersma D; van Rijn RS; Stevense-den Boer MAM; van der Veldt AAM; Vreugdenhil G; Bonenkamp HJ; Boers-Sonderen MJ; Blokx WAM; Wouters MWJM; Suijkerbuijk KPM
    Eur J Cancer; 2022 May; 167():70-80. PubMed ID: 35395553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade.
    Susok L; Reinert D; Lukas C; Stockfleth E; Gambichler T
    Immunotherapy; 2021 Aug; 13(11):885-891. PubMed ID: 34229447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
    Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
    Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.